2024 was transformative for Vir Biotechnology. We bolstered our pipeline and focused our efforts in #InfectiousDiseases and #cancer. 2025 looks bright as we take steps to transform patients’ lives. From everyone at Vir Biotechnology, thanks for your support. Wishing you a great holiday season!
Vir Biotechnology, Inc.
Biotechnology Research
San Francisco, California 32,994 followers
Powering the Immune System to Transform Lives
About us
At Vir Biotechnology, Inc., we’re focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with leading programs in chronic hepatitis delta and chronic hepatitis B, are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and our protease-releasable masking platform in infectious disease and cancer. Explore our full pipeline here: https://bit.ly/3tr7FPm It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
- Website
-
http://www.vir.bio
External link for Vir Biotechnology, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Francisco, California
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
Get directions
1800 Owens St
Suite 900
San Francisco, California 94158, US
-
Get directions
Via Mirasole 1
Bellinzona, Ticino 6500, CH
Employees at Vir Biotechnology, Inc.
Updates
-
2025 is going to be a significant year for Vir Biotechnology. We are advancing in #oncology and #InfectiousDiseases – raising the bar for transformative therapies in areas of high unmet need. Join us at #JPM25 as we share our work towards a healthier future for patients. ➡️ https://bit.ly/4iK5Zpq
-
-
📢 Good VirBiotechnology news! We received U.S. #FDA Breakthrough Therapy and European Medicines Agency PRIME designations for tobevibart and elebsiran for the treatment of chronic #HepatitisDelta. These designations are intended to speed up the development of promising medicines for patients where there is unmet medical need. https://bit.ly/4iAaDpW
-
-
Congratulations to The World Hepatitis Alliance on a very successful inaugural #HepTestWeek! We are in awe of all you do for people living with #HepatitisB and #HepatitisDelta across the globe, and deeply value your partnership.
-
-
Join us virtually as we discuss the latest on our programs in #oncology! Tune in to our investor event to learn more about initial data from the dual-masked Phase 1 T-cell engagers along with updates on the PRO-XTEN™ platform. ➡️ Watch live here: https://bit.ly/4g8OVY3
-
Get ready for an inspiring fireside chat with our CEO Marianne De Backer, MSc, PhD, MBA at the Evercore #HealthCONx2024! Join to learn more about our latest progress in infectious disease and #oncology. ➡️ Sign up here: https://lnkd.in/g-MBhGtm
-
-
🔚 It’s a wrap 🔚 #TLM24 for #TeamVir included: two oral presentations, five posters, a multi stakeholder meeting on how to improve #HepatitisDelta diagnostics, and countless interactions with the diverse community working to advance hepatitis delta and #HepatitisB care. After the past few days connecting with KOLs, peers and patients we head home inspired and ready to advance innovation for those who are waiting.
-
-
“Hepatitis B is a high unmet medical need, and approximately 250 million people around the world are chronically infected.” - Mark Eisner, MD, Chief Medical Officer at Vir Biotechnology. Learn about the results of our phase 2 MARCH study in Healio. Read more ➡️ https://lnkd.in/gEjZxRdS #TLM24
-
In Case You Missed It! Today Vir Biotechnology held an Investor Day highlighting recent milestones in our #hepatitis program. Catch up here ➡️ https://bit.ly/4fUtJ7P #TLM24
-
📢 Positive Phase 2 data and upcoming registrational Phase 3 program in hepatitis delta 📢 We are excited to share the positive result of our Phase 2 SOLSTICE trial evaluating tobevibart and elebsiran in patients living with #HepatitisDelta. Vir Biotechnology will initiate a Phase 3 ECLIPSE registrational program in the first half of 2025. Read more here ➡️ bit.ly/3UZwrkm #TLM24